Research Progress on Immunotherapy for Non-Small Cell Lung Cancer Resistant to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
Epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)is the standard first-line treatment option for patients with advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)mutations.EGFR-TKI resistance seriously affects the prognosis of patients,and the explo-ration of the mechanism of EGFR-TKI resistance and the subsequent treatment are the difficulties and focuses of the current research.In recent years,immune checkpoint inhibitors have demonstrated significant advan-tages in the treatment of EGFR-TKI-resistant advanced NSCLC.This paper analyzes the immune related mech-anisms,immune monotherapy,immune combination targeting,chemotherapy,anti angiogenesis,dual anti-body and other treatment status of EGFR-TKI resistant NSCLC.It also elaborates on the prediction of PD-L1 expression,tumor mutation burden(TMB),EGFR mutation type and metabolic products to select the domi-nant population after EGFR-TKI resistance,in order to provide reference for the treatment research and clini-cal practice of EGFR-TKI resistant NSCLC patients.
NETL
NSTL
万方数据
